Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma | Zendy

Jia Ruan | Zendy; Peter Martin | Zendy; Bijal Shah | Zendy; Stephen J. Schuster | Zendy; Sonali M. Smith | Zendy; Richard R. Furman | Zendy; Paul J. Christos | Zendy; Á Rodríguez | Zendy; Jakub Svoboda | Zendy; Jessica Lewis | Zendy; Orel Katz | Zendy; Morton Coleman | Zendy; John P. Leonard | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma

Author(s) -

Jia Ruan,

Peter Martin,

Bijal Shah,

Stephen J. Schuster,

Sonali M. Smith,

Richard R. Furman,

Paul J. Christos,

Á Rodríguez,

Jakub Svoboda,

Jessica Lewis,

Orel Katz,

Morton Coleman,

John P. Leonard

Publication year - 2015

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1505237

Subject(s) - medicine , mantle cell lymphoma , lenalidomide , rituximab , neutropenia , rash , adverse effect , febrile neutropenia , clinical endpoint , gastroenterology , lymphoma , surgery , oncology , multiple myeloma , chemotherapy , clinical trial

Mantle-cell lymphoma is generally incurable. Initial treatment is not standardized but usually includes cytotoxic chemotherapy. Lenalidomide, an immunomodulatory compound, and rituximab, an anti-CD20 antibody, are active in patients with recurrent mantle-cell lymphoma. We evaluated lenalidomide plus rituximab as a first-line therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research